id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-E-2617-0004,FDA,FDA-2018-E-2617,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,,2019-12-12T17:33:46Z,,0,0,0900006484208552
FDA-2018-E-2617-0003,FDA,FDA-2018-E-2617,"Determination of Regulatory Review Period for Purposes of Patent
Extension; VABOMERE",Notice,Determinations,2019-12-11T05:00:00Z,2019,12,2019-12-11T05:00:00Z,2020-02-11T04:59:59Z,2019-12-12T14:42:41Z,2019-26655,0,0,0900006484200d32
FDA-2018-E-2617-0002,FDA,FDA-2018-E-2617,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-07-24T04:00:00Z,2019,7,2019-07-24T04:00:00Z,,2019-07-24T14:50:26Z,,0,0,0900006483db162e